In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

The reported valuation aligns with where Manus had been headed before Meta intervened. The company had been raising new funds ...